RU2002128004A - Содержащие гетероциклическую боковую цепь ингибиторы металлопротеиназы - Google Patents
Содержащие гетероциклическую боковую цепь ингибиторы металлопротеиназыInfo
- Publication number
- RU2002128004A RU2002128004A RU2002128004/04A RU2002128004A RU2002128004A RU 2002128004 A RU2002128004 A RU 2002128004A RU 2002128004/04 A RU2002128004/04 A RU 2002128004/04A RU 2002128004 A RU2002128004 A RU 2002128004A RU 2002128004 A RU2002128004 A RU 2002128004A
- Authority
- RU
- Russia
- Prior art keywords
- group
- heterocycloalkyl
- alkyl
- heteroalkyl
- hydrogen
- Prior art date
Links
- 239000003475 metalloproteinase inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000004404 heteroalkyl group Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims 17
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 17
- 125000003342 alkenyl group Chemical group 0.000 claims 16
- 125000000304 alkynyl group Chemical group 0.000 claims 16
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 15
- 125000004429 atom Chemical group 0.000 claims 15
- 125000001188 haloalkyl group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000005842 heteroatom Chemical group 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 1
- 150000003949 imides Chemical class 0.000 claims 1
- 238000009776 industrial production Methods 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D309/06—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Claims (14)
1. Соединение, имеющее структуру, соответствующую формуле (I)
отличающееся тем, что
(A) R1 выбран из -ОН и -NHOH;
(B) R2 выбран из группы, включающей водород, алкил, алкенил, алкинил, гетероалкил, галогеналкил, циклоалкилалкил, гетероциклоалкилалкил, арилалкил и гетероарилалкил;
(C) А означает замещенный или незамещенный моноциклический гетероциклоалкил с 3-8 атомами в кольце, из которых 1-3 являются гетероатомами; или А может быть связан с R2, где вместе они образуют замещенный или незамещенный моноциклический гетероциклоалкил с 3-8 атомами в кольце, из которых 1-3 являются гетероатомами;
(D) n = 0-4;
(Е) Е выбран из группы, включающей ковалентную связь, С1-С4-алкил, -С(=O)-, -С(=O)O-, C(=O)N(R3)-, -SO2 и -C(=S)N(R3)-, где R3 выбран из группы, включающей водород, алкил, алкенил, алкинил, гетероалкил, галогеналкил, циклоалкил, гетероциклоалкил, арил, арилалкил, гетероарил и гетероарилалкил;
(F) X выбран из группы, включающей водород, алкил, алкенил, алкинил, гетероалкил, галогеналкил, арил, арилалкил, гетероарил, гетероарилалкил, циклоалкил, гетероциклоалкил, -C(=O)R4, -C(=O)OR4, -C(=O)NR4R4’ и -SO2R4, где R4 и R4’ независимо выбраны из группы, включающей: водород, алкил, алкенил, алкинил, гетероалкил, галогеналкил, циклоалкил, гетероциклоалкил, арил, арилалкил, гетероарил и гетероарилалкил; или Х и R3 соединены, образуя замещенный или незамещенный моноциклический гетероциклоалкил с 3-8 атомами в кольце, из которых 1-3 являются гетероатомами;
(G) G выбран из группы, включающей: -S-, -О-, -N(R5)-, -C(R5)=C(R5’)-, -N=C(R5)- и -N=N-, где каждый из R5 и R5’ независимо выбраны из группы, включающей: водород, алкил, алкенил, алкинил, гетероалкил, арил, гетероарил, циклоалкил и гетероциклоалкил;
(Н) Z выбран из группы, включающей (1) циклоалкил и гетероциклоалкил; (2) -L-(CR6R6’)aR7,
где (a) а = 0-4;
(b) L выбран из группы, включающей: -C≡C-, -CH=CH-, -N=N-, -О-, -S- и -SO2-;
(c) каждый из R6 и R6’ независимо выбран из группы, включающей водород, алкил, алкенил, алкинил, арил, гетероалкил, гетероарил, циклоалкил, гетероциклоалкил, галоген, галогеналкил, гидрокси и алкокси;
(d) R7 выбран из группы, включающей: водород, арил, гетероарил, алкил, алкенил, алкинил, гетероалкил, галогеналкил, гетероциклоалкил и циклоалкил; и, если L означает -С=С- или -СН=СН-, то R7 может также быть выбран из –C(=O)NR8R8’, где (i) R8 и R8’ независимо выбраны из группы, включающей: водород, алкил, алкенил, алкинил, галогеналкил, гетероалкил, арил, гетероарил, циклоалкил и гетероциклоалкил, или (ii) R8 и R8’, вместе с атомом азота, к которому они присоединены, объединены с образованием необязательно замещенного гетероцикла с 5-8 атомами в кольце, из которых 1-3 являются гетероатомами;
(3) –NR9R9’,
где (а) каждый из R9 и R9’ независимо выбран из группы, включающей: водород, алкил, алкенил, алкинил, гетероалкил, галогеналкил, арил, гетероарил, циклоалкил, гетероалкил и -С (=O)-Q-[CR10R10’)bR11,
где (i) b = 0-4;
(ii) Q выбран из ковалентной связи и -N(R12)-;
(iii) каждый из R10 и R10' независимо выбран из группы, включающей: водород, алкил, алкенил, алкинил, арил, гетероалкил, гетероарил, циклоалкил, гетероциклоалкил, галоген, галогеналкил, гидрокси и алкокси; R11 и R12 (i) каждый независимо выбран из группы, включающей: водород, алкил, алкенил, алкинил, гетероалкил, галогеналкил, арил, гетероарил, циклоалкил и гетероциклоалкил, или (ii) вместе с атомами, с которыми они связаны, объединены с образованием необязательно замещенного гетероцикла с 5-8 атомами в кольце, из которых 1-3 являются гетероатомами; или R9 и R12, вместе с атомами азота, с которыми они связаны, объединены с образованием необязательно замещенного гетероцикла с 5-8 атомами в кольце, из которых 2-3 являются гетероатомами; или
(b) R9 и R9’, вместе с атомом азота, с которым они связаны, объединены с образованием необязательно замещенного гетероцикла с 5-8 атомами в кольце, из которых 1-3 являются гетероатомами; и
где (a) Е’ и М независимо выбраны из группы, включающей -СН- и -N-;
(b) L’ выбран из группы, включающей -S-, -О-, -N(R14)-, -С(R14)=С(R14’),-N=C(R14)- и -N=N-, где каждый из R14 и R14’ независимо выбран из группы, включающей водород, алкил, алкенил, алкинил, гетероалкил, арил, гетероарил, циклоалкил и гетероциклоалкил;
(c) с = 0-4;
(d) каждый из R13 и R13’ независимо выбран из группы, включающей водород, алкил, алкенил, алкинил, арил, гетероалкил, гетероарил, циклоалкил, гетероциклоалкил, галоген, галогеналкил, гидрокси и алкокси;
(e) А’ выбран из группы, включающей ковалентную связь, -О-, -SOd-, -C(=O)-, -C(=O)N(R15)-, -N(R15)- и -N(R15)С(=O)-; где d равно 0-2 и R15 выбран из группы, включающей: водород, алкил, алкенил, алкинил, арил, гетероарил, гетероалкил, гетероарил, циклоалкил, гетероциклоалкил и галогеналкил;
(f) G’ означает - (CR16R16’)e-R17,
где е равно 0-4;
каждый из R16 и R16’ независимо выбран из группы, включающей: водород, алкил, алкенил, алкинил, арил, гетероалкил, гетероарил, циклоалкил, гетероциклоалкил, галоген, галогеналкил, гидрокси, алкокси и арилокси; и R17 выбран из группы, включающей: водород, алкил, алкенил, алкинил, галоген, гетероалкил, галогеналкил, арил, гетероарил, циклоалкил и гетероциклоалкил; или R16 и R17, вместе с атомами, с которыми они связаны, объединены с образованием необязательно замещенного гетероцикла с 5-8 атомами в кольце, из которых 1-3 являются гетероатомами; или R13 и R17, вместе с атомами, с которыми они связаны, объединены с образованием необязательно замещенного гетероцикла с 5-8 атомами в кольце, из которых 1-3 являются гетероатомами;
или оптический изомер, диастереомер или энантиомер для формулы (I), или их фармацевтически приемлемая соль, или биогидролизуемый амид, сложный эфир или имид.
2. Соединение по п.1, отличающееся тем, что А и R2 не объединяются с образованием кольца, и что А означает замещенный или незамещенный моноциклический гетероциклоалкил с 3-8 атомами в кольце и 1-3 гетероатомами в кольце.
3. Соединение по п.1, отличающееся тем, что А и R2 вместе образуют замещенный или незамещенный моноциклический гетероциклоалкил с 3-8 атомами в кольце и 1-3 гетероатомами в кольце.
4. Соединение по любому из пп.1, 2 или 3, отличающееся тем, что Х выбран из группы, включающей водород, алкил, гетероалкил, арил, арилалкил, гетероарил, гетероарилалкил, циклоалкил или гетероциклоалкил.
5. Соединение по любому из пп.1, 2 или 3, отличающееся тем, что Х и R3 объединены с образованием замещенного или незамещенного моноциклического гетероциклоалкила с 3-8 атомами в кольце и 1-3 гетероатомами в кольце.
6. Соединение по любому из предшествующих пунктов, отличающееся тем, что G выбран из -S- и -СН=СН-.
7. Соединение по любому из предшествующих пунктов, отличающееся тем, что Z выбран из группы, включающей
-L-(CR6R6’)aR7; -NR9R9’ и
8. Соединение по любому из предшествующих пунктов, отличающееся тем, что Е выбран из группы, включающей ковалентную связь, C1-С3-алкил, -С(=O), -С(=O)O-, -C(=O)N(R3)-и –SO2-.
9. Соединение по любому из предшествующих пунктов, отличающееся тем, что R2 выбран из группы, включающей водород и алкил.
10. Соединение по любому из предшествующих пунктов, отличающееся тем, что n = 0 или 1.
11. Фармацевтическая композиция, включающая (a) безопасное и эффективное количество соединения по любому из предшествующих пунктов и (b) фармацевтически приемлемый носитель.
12. Применение соединения по любому из предшествующих пунктов для промышленного получения лекарственного средства для лечения заболевания, связанного с нежелательной активностью металлопротеаз в организме млекопитающего.
13. Применение по п.12, отличающееся тем, что указанным заболеванием является артрит и оно выбрано из группы, включающей остеоартрит и ревматоидный артрит.
14. Применение по п.12, отличающееся тем, что указанным нарушением является раковая опухоль, и данное лечение предупреждает или останавливает рост опухолей и метастазов.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19130300P | 2000-03-21 | 2000-03-21 | |
| US60/191,303 | 2000-03-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2002128004A true RU2002128004A (ru) | 2004-02-27 |
| RU2230736C2 RU2230736C2 (ru) | 2004-06-20 |
Family
ID=22704942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002128004/04A RU2230736C2 (ru) | 2000-03-21 | 2001-03-20 | Содержащие гетероциклическую боковую цепь ингибиторы металлопротеиназы и фармацевтическая композиция |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20030171400A1 (ru) |
| EP (1) | EP1265863A1 (ru) |
| JP (1) | JP2003528079A (ru) |
| KR (1) | KR20020081464A (ru) |
| CN (1) | CN1418193A (ru) |
| AR (1) | AR033356A1 (ru) |
| AU (1) | AU2001245863A1 (ru) |
| BR (1) | BR0109353A (ru) |
| CA (1) | CA2404076A1 (ru) |
| CZ (1) | CZ20023180A3 (ru) |
| HU (1) | HUP0300262A2 (ru) |
| IL (1) | IL151124A0 (ru) |
| MA (1) | MA25782A1 (ru) |
| MX (1) | MXPA02009312A (ru) |
| NO (1) | NO20024521L (ru) |
| NZ (1) | NZ520656A (ru) |
| PE (1) | PE20011189A1 (ru) |
| PL (1) | PL357250A1 (ru) |
| RU (1) | RU2230736C2 (ru) |
| SK (1) | SK13352002A3 (ru) |
| WO (1) | WO2001070690A1 (ru) |
| ZA (1) | ZA200206297B (ru) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE467629T1 (de) * | 2001-03-14 | 2010-05-15 | Novartis Pharma Gmbh | Azacycloalkyl-substituierte essigsäure-derivate zur verwendung als mmp-inhibitoren |
| CN1950354A (zh) | 2004-05-11 | 2007-04-18 | 默克公司 | N－磺酰化－氨基酸衍生物的制备方法 |
| US7576222B2 (en) | 2004-12-28 | 2009-08-18 | Wyeth | Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase |
| CA2670704A1 (en) * | 2006-11-29 | 2008-06-05 | Mallinckrodt Inc. | New process for remifentanil synthesis |
| WO2009096198A1 (ja) * | 2008-02-01 | 2009-08-06 | Pharma Ip Limited Liability Intermediary Corporations | 新規ビアリール誘導体 |
| EP2836482B1 (en) * | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| MX382355B (es) | 2015-04-10 | 2025-03-13 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos. |
| MX2017013275A (es) | 2015-04-15 | 2018-01-26 | Araxes Pharma Llc | Inhibidores triciclicos fusionados de kras y metodos de uso de los mismos. |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017058792A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| KR20180081596A (ko) | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| JP2019529484A (ja) | 2016-09-29 | 2019-10-17 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤 |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| WO2018140600A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
| WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
| US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
| CN110869357A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
| KR20200010306A (ko) | 2017-05-25 | 2020-01-30 | 아락세스 파마 엘엘씨 | Kras의 공유적 억제제 |
| US12134620B2 (en) | 2018-08-01 | 2024-11-05 | Araxes Pharma Llc | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer |
| GB201905520D0 (en) | 2019-04-18 | 2019-06-05 | Modern Biosciences Ltd | Compounds and their therapeutic use |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5646167A (en) * | 1993-01-06 | 1997-07-08 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamix acids |
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| GB9411088D0 (en) * | 1994-06-03 | 1994-07-27 | Hoffmann La Roche | Hydroxylamine derivatives |
| CA2193691A1 (en) * | 1994-06-22 | 1995-12-28 | Andrew Miller | Metalloproteinase inhibitors |
| GB9416897D0 (en) * | 1994-08-20 | 1994-10-12 | British Biotech Pharm | Metalloproteinase inhibitors |
| IL115995A0 (en) * | 1994-11-15 | 1996-01-31 | Bayer Ag | Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors |
| US5886022A (en) * | 1995-06-05 | 1999-03-23 | Bayer Corporation | Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors |
| US6124333A (en) * | 1995-06-22 | 2000-09-26 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
| TR199901849T2 (xx) * | 1997-02-03 | 2000-02-21 | Pfizer Products Inc. | Arils�lfonilamino hidroksamik asit t�revleri. |
| DE19719621A1 (de) * | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| EP1009737A2 (en) * | 1997-07-31 | 2000-06-21 | The Procter & Gamble Company | Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors |
| EP1053226A1 (en) * | 1998-02-04 | 2000-11-22 | Novartis AG | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
| PA8469501A1 (es) * | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| US6225311B1 (en) * | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
| MXPA01008857A (es) * | 1999-03-03 | 2002-07-02 | Procter & Gamble | Inhibidores de metaloproteasa dihetero sustituidos. |
| HN2000000052A (es) * | 1999-05-28 | 2001-02-02 | Pfizer Prod Inc | Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos. |
| CA2375524C (en) * | 1999-05-28 | 2006-11-28 | Lawrence Alan Reiter | 3-(arylsulfonylamino)-tetrahydropyran-3-carboxylic acid hydroxamides |
| SK12842002A3 (sk) * | 2000-03-21 | 2003-02-04 | The Procter And Gamble Company | Heterocyklický vedľajší reťazec obsahujúci N-substituované inhibítory metaloproteáz a farmaceutický prípravok s ich obsahom |
-
2001
- 2001-03-20 JP JP2001568902A patent/JP2003528079A/ja not_active Withdrawn
- 2001-03-20 KR KR1020027012312A patent/KR20020081464A/ko not_active Ceased
- 2001-03-20 HU HU0300262A patent/HUP0300262A2/hu unknown
- 2001-03-20 WO PCT/US2001/008783 patent/WO2001070690A1/en not_active Ceased
- 2001-03-20 PL PL01357250A patent/PL357250A1/xx not_active Application Discontinuation
- 2001-03-20 AR ARP010101311A patent/AR033356A1/es not_active Application Discontinuation
- 2001-03-20 CN CN01806654A patent/CN1418193A/zh active Pending
- 2001-03-20 SK SK1335-2002A patent/SK13352002A3/sk unknown
- 2001-03-20 RU RU2002128004/04A patent/RU2230736C2/ru not_active IP Right Cessation
- 2001-03-20 NZ NZ520656A patent/NZ520656A/en unknown
- 2001-03-20 IL IL15112401A patent/IL151124A0/xx unknown
- 2001-03-20 BR BR0109353-3A patent/BR0109353A/pt not_active IP Right Cessation
- 2001-03-20 EP EP01918833A patent/EP1265863A1/en not_active Withdrawn
- 2001-03-20 CA CA002404076A patent/CA2404076A1/en not_active Abandoned
- 2001-03-20 CZ CZ20023180A patent/CZ20023180A3/cs unknown
- 2001-03-20 MX MXPA02009312A patent/MXPA02009312A/es unknown
- 2001-03-20 AU AU2001245863A patent/AU2001245863A1/en not_active Abandoned
- 2001-03-21 PE PE2001000264A patent/PE20011189A1/es not_active Application Discontinuation
-
2002
- 2002-08-07 ZA ZA200206297A patent/ZA200206297B/en unknown
- 2002-09-16 MA MA26818A patent/MA25782A1/fr unknown
- 2002-09-18 US US10/246,201 patent/US20030171400A1/en not_active Abandoned
- 2002-09-20 NO NO20024521A patent/NO20024521L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1265863A1 (en) | 2002-12-18 |
| CZ20023180A3 (cs) | 2003-02-12 |
| WO2001070690A1 (en) | 2001-09-27 |
| NO20024521D0 (no) | 2002-09-20 |
| NZ520656A (en) | 2004-05-28 |
| US20030171400A1 (en) | 2003-09-11 |
| CA2404076A1 (en) | 2001-09-27 |
| KR20020081464A (ko) | 2002-10-26 |
| HUP0300262A2 (hu) | 2003-06-28 |
| AR033356A1 (es) | 2003-12-17 |
| ZA200206297B (en) | 2003-02-17 |
| MXPA02009312A (es) | 2003-03-12 |
| AU2001245863A1 (en) | 2001-10-03 |
| IL151124A0 (en) | 2003-04-10 |
| PE20011189A1 (es) | 2001-12-11 |
| MA25782A1 (fr) | 2003-07-01 |
| JP2003528079A (ja) | 2003-09-24 |
| PL357250A1 (en) | 2004-07-26 |
| NO20024521L (no) | 2002-09-20 |
| BR0109353A (pt) | 2003-04-08 |
| RU2230736C2 (ru) | 2004-06-20 |
| CN1418193A (zh) | 2003-05-14 |
| SK13352002A3 (sk) | 2003-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002128004A (ru) | Содержащие гетероциклическую боковую цепь ингибиторы металлопротеиназы | |
| RU2002128007A (ru) | Содержащие гетероциклическую боковую цепь n-замещенные ингибиторы металлопротеазы | |
| RU2403251C2 (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 | |
| RU2011103234A (ru) | Новые фенилпиразиноны в качестве ингибиторов киназы | |
| RU2005102004A (ru) | Замещенные хинолины как антагонисты рецептора ccr5 | |
| RU2004130488A (ru) | Пиримидиновые производные | |
| RU2009117642A (ru) | Применение спирооксиндоловых соединений в качестве терапевтических средств | |
| RU2007128987A (ru) | 3,4-дигидро-1н-изохинолин-2-карбоновой кислоты 5-аминопиридин-2-2-иловые эфиры | |
| RU2005128775A (ru) | Производные пиперидинбензолсульфамида | |
| RU95120598A (ru) | Производные 10,11-метандибензосуберана, используемые в качестве хемосенсибилизующих агентов | |
| RU2004111979A (ru) | Производные 1н-имидазола, обладающие св1-агонистической, частичной св1-агонистической или св1-антагонистической активностью | |
| RU2001122727A (ru) | Амиды кислот, способ их получения и фармацевтическая композиция на их основе | |
| RU2000125568A (ru) | Производные циклоалкенов, их получение и применение | |
| RU95117068A (ru) | Антигипертриглицеридемическая композиция, способ ее получения, способ лечения или профилактики гипертриглицеридемии, применение соединений | |
| RU2004118423A (ru) | Производные бензотиазола в качестве лигандов рецептора аденозина | |
| RU2012109220A (ru) | Новые соединения и их терапевтическое использование для ингибирования протеинкиназы | |
| RU2002128015A (ru) | Содержащие карбоциклическую боковую цепь n-замещенные ингибиторы металлопротеаз | |
| RU2008125040A (ru) | ПРОИЗВОДНЫЕ АРИЛ-ИЗОКСАЗОЛ-4-ИЛ-ИМИДАЗО[1.5-a]ПИРИДИНА | |
| RU2005121908A (ru) | Производные зн-хиназолин-4-она | |
| RU2003130644A (ru) | Производные ркарболина и их фармацевтическое применение против дипрессии и страха | |
| RU2007124491A (ru) | Замещенные производные бензохинолизина | |
| RU2006124513A (ru) | Производные бензоксазина и их применение | |
| RU2006113942A (ru) | Производные бензимидазолона и хиназолина как ангонисты orl-рецепторов человека | |
| RU98117245A (ru) | 2-(арилфенил)аминоимидазолиновые производные | |
| RU2005128793A (ru) | Химические соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20060321 |